fbpx
QQQ
+ 2.58
328.93
+ 0.78%
DIA
+ 2.29
343.25
+ 0.66%
SPY
+ 2.93
416.17
+ 0.7%
TLT
-0.69
140.61
-0.49%
GLD
+ 1.55
168.49
+ 0.91%

Cybin Partners With Toronto Centre For Psychedelic Science For Psilocybin Research Project

February 13, 2020 4:50 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Cybin Partners With Toronto Centre For Psychedelic Science For Psilocybin Research Project

Cybin Corp., a Canadian life sciences company focused on psychedelics and mushroom-psilocybin research, announced a new partnership with the Toronto Centre for Psychedelic Science.

With this partnership, the centers' co-founders, Rotem Petranker and Thomas Anderson will be appointed exclusive clinical advisors to Cybin.

"We feel many of the positive results that people have experienced with psychedelics require further scientific study with transparently-disclosed protocols and proper research study architecture to achieve repeatable results," Paul Glavine, CEO of Cybin Corp. told Benzinga. "Rotem and Thomas' commitment to open science echoes our philosophy. Together we expect to build a solid foundation and future for this industry, grounded in research and the scientific method."

Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science said, "We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development."

Related Links:

The Keys To Understanding Psilocybin's Medical Value, Market Potential

Will Shroom Dispensaries Become A Thing Anytime Soon?

Posted-In:

Cannabis Markets

Related Articles

The Benefits Of Peyote: Ancient Wisdom, Modern Medicine

This article by Evan Lewis-Healey was originally published on Psychedelic Spotlight, and appears here with permission. read more

How Psychedelics Without Hallucinogenic Effects Could Revolutionize Psychiatry

A new study published in the peer-review journal Cell looks at a novel compound capable of providing some of the therapeutic properties of psychedelics without hallucinations. read more

Novamind And Field Trip Expand Footprint Of Psychedelic Clinics

Novamind Inc. (OTCPink: NVMDF), a company specializing in mental health and psychedelics treatment, announced on Tuesday it intends to open four new psychiatry clinics in Utah. read more

World's First Phase 3 Clinical Trial On MDMA Shows 'Powerful New Pathway To Healing'

The results from the world’s first Phase 3 clinical study on a psychedelic are in — and they’re significant. The Multidisciplinary Association for Psychedelic Studies released the results from its Phase 3 trial on MDMA for the treatment of post-traumatic stress disorder.  read more